Vironexis develops off-the-shelf T-cell immuno-gene therapies using its TransJoin™ AAV Gene Therapy Platform. This approach delivers a single-dose treatment designed to redirect T cells for durable, steady-state tumor killing without custom manufacturing. The company is advancing a pipeline of candidates targeting blood-based cancers, solid tumor metastasis prevention, and cancer vaccines.
Funding
$52M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing T-cell immunotherapies for cancer face limitations, including safety concerns, the complexities of custom manufacturing, and challenges in scaling treatments for large patient populations. These issues hinder the widespread accessibility and effectiveness of T-cell immunotherapy.
Solution
Vironexis is developing off-the-shelf, single-dose T-cell immunotherapies delivered via adeno-associated virus (AAV) gene therapy to enhance T-cell targeting of tumor cells. The TransJoin™ platform enables the expression of an engineered transgene that redirects T cells throughout the body to tumor cells, promoting durable T-cell-mediated tumor killing without the need for pre-treatment or custom manufacturing. This approach aims to improve the safety, efficacy, and scalability of cancer immunotherapies. The company is advancing a pipeline of product candidates for blood-based cancers, solid tumor metastasis prevention, and cancer prevention through a vaccine.
Target Audience
The primary target audience includes patients with various cancers, as well as oncologists and medical professionals seeking more effective and accessible immunotherapy options.
Features
- TransJoin™ AAV gene therapy platform for off-the-shelf T-cell immunotherapies
- AAV-delivered T-cell redirection for enhanced tumor cell targeting
- Single-dose infusion without pre-treatment or custom manufacturing
- Pipeline of 10+ product candidates across blood-based cancers, solid tumors, and cancer prevention
- VNX-101: AAV-delivered immunotherapy targeting CD19 for Acute Lymphoblastic Leukemia (ALL) with FDA Fast Track and Orphan Drug Designations
- VNX-102: Immunotherapy targeting BCMA/GPRC5D for Multiple Myeloma
- VNX-201: Immunotherapy targeting GD2 for Neuroblastoma